Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery

NCT02547987 is registered in ClinicalTrials.gov with Mothaffar Rimawi as lead sponsor.

NCT NCT02547987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02547987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery
Lead sponsor
Mothaffar Rimawi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 1, 2015
Completion date
September 30, 2025
Enrollment
25 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer